Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas

in European Journal of Endocrinology
Correspondence should be addressed to A G Ioachimescu; Email: aioachi@emory.edu
Restricted access

24-hour access to this article

USD $30.00

Background

Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs’ psychological side effects, either de novo or as exacerbations of prior psychiatric disease.

Methods

Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Case series and case reports of psychiatric complications were also reviewed.

Results

Most studies were cross-sectional and had a control group of healthy volunteers or patients with nonfunctioning pituitary adenomas. There were few prospective studies, with/without control group, that included small numbers of patients. Compared with controls, patients with hyperprolactinemia generally had worse quality of life, anxiety, depression and certain personality traits. Patients receiving DAs had higher impulsivity scores than normoprolactinemic controls. Impulse control disorders (ICDs) were reported in both genders, with hypersexuality mostly in men. Multiple ICDs were sometimes reported in the same patient, usually reversible after DA discontinuation. In case reports, DA therapy was temporally associated with severe depression, manic episodes or psychosis, which improved after discontinuation and administration of psychiatric medications. Gender type of DA, dose and duration of therapy did not correlate with occurrence of psychiatric pathology.

Conclusion

Patients with hyperprolactinemia receiving DAs may develop changes in mood and behavior regardless of prior psychiatric history. Increased awareness for ICDs, depression, mania and other types of psychosis is needed by all physicians who prescribe DAs. Larger prospective controlled clinical studies are needed to delineate prevalence, risk stratification and management.

 

Official journal of

European Society of Endocrinology

Sections

References

1

MelmedSCasanuevaFFHoffmanARKleinbergDLMontoriVMSchlechteJAWassJAEndocrineS. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 273288. (https://doi.org/10.1210/jc.2010-1692)

2

ChansonPMaiterD. Prolactinoma. In Pituitaryedn 4 ch 16 pp 467514. Ed MelmedS. Elsevier2017. (https://doi.org/10.1016/B978-0-12-804169-7.00016-7)

3

MolitchME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017 317 516524. (https://doi.org/10.1001/jama.2016.19699)

4

Grall-BronnecMVictorri-VigneauCDonnioYLeboucherJRousseletMThiabaudEZreikaNDerkinderenPChallet-BoujuG. Dopamine agonists and impulse control disorders: a complex association. Drug Safety 2018 41 1975. (https://doi.org/10.1007/s40264-017-0590-6)

5

Ben-JonathanNHnaskoR. Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews 2001 22 724763. (https://doi.org/10.1210/edrv.22.6.0451)

6

GhahremaniDGLeeBRobertsonCLTabibniaGMorganATDe ShetlerNBrownAKMonterossoJRAronARMandelkernMA et al. Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. Journal of Neuroscience 2012 32 73167324. (https://doi.org/10.1523/JNEUROSCI.4284-11.2012)

7

NoronhaSStokesVKaravitakiNGrossmanA. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 2016 51 205210. (https://doi.org/10.1007/s12020-015-0727-2)

8

BarlierAJaquetP. Quinagolide – a valuable treatment option for hyperprolactinaemia. European Journal of Endocrinology 2006 154 187195. (https://doi.org/10.1530/eje.1.02075)

9

AhlskogJE. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiology and Behavior 2011 104 168172. (https://doi.org/10.1016/j.physbeh.2011.04.055)

10

SeemanP. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015 69 183189. (https://doi.org/10.1002/syn.21805)

11

AthanasouliaAPSieversCIsingMBrockhausACYassouridisAStallaGKUhrM. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. European Journal of Endocrinology 2012 167 327335. (https://doi.org/10.1530/EJE-12-0198)

12

SobrinhoLG. Prolactin, psychological stress and environment in humans: adaptation and maladaptation. Pituitary 2003 6 3539. (https://doi.org/10.1023/A:1026229810876)

13

FavaGAFavaMKellnerRSerafiniEMastrogiacomoI. Depression hostility and anxiety in hyperprolactinemic amenorrhea. Psychotherapy and Psychosomatics 1981 36 122128. (https://doi.org/10.1159/000287535)

14

KellnerRBuckmanMTFavaGAPathakD. Hyperprolactinemia, distress, and hostility. American Journal of Psychiatry 1984 141 759763. (https://doi.org/10.1176/ajp.141.6.759)

15

ZacurHAChapanisNPLakeCRZieglerMTysonJE. Galactorrhea-amenorrhea: psychological interaction with neuroendocrine function. American Journal of Obstetrics and Gynecology 1976 125 859862. (https://doi.org/10.1016/0002-9378(76)90863-2)

16

BuckmanMTKellnerR. Reduction of distress in hyperprolactinemia with bromocriptine. American Journal of Psychiatry 1985 142 242244. (https://doi.org/10.1176/ajp.142.2.242)

17

FavaMFavaGAKellnerRBuckmanMTLisanskyJSerafiniEDeBesiLMastrogiacomoI. Psychosomatic aspects of hyperprolactinemia. Psychotherapy and Psychosomatics 1983 40 257262. (https://doi.org/10.1159/000287773)

18

RoccoAMoriFBaldelliRAversaAMunizziMRNardoneMRFabbriniAFalaschiP. Effect of chronic bromocriptine treatment on psychological profile of patients with PRL-secreting pituitary adenomas. Psychoneuroendocrinology 1993 18 5766. (https://doi.org/10.1016/0306-4530(93)90055-P)

19

JohnsonMDWoodburnCJVanceML. Quality of life in patients with a pituitary adenoma. Pituitary 2003 6 8187. (https://doi.org/10.1023/B:PITU.0000004798.27230.ed)

20

KarsMvan der KlaauwAAOnsteinCSPereiraAMRomijnJA. Quality of life is decreased in female patients treated for microprolactinoma. European Journal of Endocrinology 2007 157 133139. (https://doi.org/10.1530/EJE-07-0259)

21

AthanasouliaAPIsingMPfisterHMantzorosCSStallaGKSieversC. Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 2012 96 204211. (https://doi.org/10.1159/000335996)

22

CelikEOzkayaHMPoyrazBCSaglamTKadiogluP. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine 2018 Epub.

23

MooreTJGlenmullenJMattisonDR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Internal Medicine 2014 174 19301933.

24

Athanasoulia-KasparAPPoppKHStallaGK. Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocrine Connections 2018 7 R88R94. (https://doi.org/10.1530/EC-18-0030)

25

BastiaensJDorfmanBJChristosPJNirenbergMJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Movement Disorders 2013 28 327333. (https://doi.org/10.1002/mds.25291)

26

van HolstRJvan den BrinkWVeltmanDJGoudriaanAE. Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neuroscience and Biobehavioral Reviews 2010 34 87107. (https://doi.org/10.1016/j.neubiorev.2009.07.007)

27

DavieM. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. Journal of Neuropsychiatry and Clinical Neurosciences 2007 19 473474. (https://doi.org/10.1176/jnp.2007.19.4.473)

28

AlmanzarSZapata-VegaMIRayaJA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics 2013 54 387391. (https://doi.org/10.1016/j.psym.2012.10.002)

29

FalhammarHYarkerJY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Medical Journal of Australia 2009 190 97.

30

ThondamSKAlusiSO'DriscollKGilkesCECuthbertsonDJDaousiC. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clinical Neuropharmacology 2013 36 170172. (https://doi.org/10.1097/WNF.0b013e31829fc165)

31

VinkersDJvan der WeeNJ. A case of mania after long-term use of quinagolide. General Hospital Psychiatry 2007 29 464. (https://doi.org/10.1016/j.genhosppsych.2007.05.004)

32

De SousaSMChapmanIMFalhammarHTorpyDJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 2017 55 618624. (https://doi.org/10.1007/s12020-016-1088-1)

33

BancosINannengaMRBostwickJMSilberMHEricksonDNippoldtTB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clinical Endocrinology 2014 80 863868. (https://doi.org/10.1111/cen.12375)

34

MartinkovaJTrejbalovaLSasikovaMBenetinJValkovicP. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clinical Neuropharmacology 2011 34 179181. (https://doi.org/10.1097/WNF.0b013e3182281b2f)

35

BulwerCConnRShankarAFerrauFKapurSEderiesAKorbonitsMSpoudeasHA. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clinical Endocrinology 2017 86 862864. (https://doi.org/10.1111/cen.13339)

36

BarakeMEvinsAEStoeckelLPachasGNNachtigallLBMillerKKBillerBMTritosNAKlibanskiA. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 2014 17 150156. (https://doi.org/10.1007/s11102-013-0480-6)

37

BurbackL. Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania. Endocrinology Diabetes and Metabolism Case Reports 2015 2015 150100.

38

BakkerICSchubartCDZelissenPM. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole. Endocrinology Diabetes and Metabolism Case Reports 2016 2016 160028.

39

RoveraCCremaschiLThanjuAFiorentiniAMauriMCSeratiMLindenmayerJPAltamuraAC. Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. Asian Journal of Psychiatry 2016 22 9495. (https://doi.org/10.1016/j.ajp.2016.05.010)

40

FreemanBLevyWGormanJM. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. Journal of Psychiatric Practice 2007 13 120124. (https://doi.org/10.1097/01.pra.0000265771.47153.a0)

41

SheldrickAJGrunderG. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Pharmacopsychiatry 2008 41 160. (https://doi.org/10.1055/s-2008-1076721)

42

Al-SemaanYMClayHAMeltzerHY. Clozapine in treatment of bromocriptine-induced psychosis. Journal of Clinical Psychopharmacology 1997 17 126128. (https://doi.org/10.1097/00004714-199704000-00016)

43

PeterSAAutzAJean-SimonML. Bromocriptine-induced schizophrenia. Journal of the National Medical Association 1993 85 700701.

44

CabezaGAFloresLFIniguezIECalarcoZEValenciaPF. Acute psychosis secondary to bromocriptine treatment in a patient with a prolactinoma. Revista de Investigación Clínica 1984 36 147149.

45

BilalLChingC. Cabergoline-induced psychosis in a patient with undiagnosed depression. Journal of Neuropsychiatry and Clinical Neurosciences 2012 24 E54. (https://doi.org/10.1176/appi.neuropsych.11110348)

46

MohapatraSNayakMR. Cabergoline-induced mania in a patient of pituitary microadenoma. Indian Journal of Psychological Medicine 2017 39 350351. (https://doi.org/10.4103/0253-7176.207314)

47

TurnerTHCooksonJCWassJADruryPLPricePABesserGM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. BMJ 1984 289 11011103. (https://doi.org/10.1136/bmj.289.6452.1101)

48

AliSMillerKKFreudenreichO. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 2010 51 370376. (https://doi.org/10.1016/S0033-3182(10)70718-0)

49

YukselRNElyas KayaZDilbazNCingi YirunM. Cabergoline-induced manic episode: case report. Therapeutic Advances in Psychopharmacology 2016 6 229231. (https://doi.org/10.1177/2045125315626345)

50

HofferZSRothRLMathewsM. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009 50 317324. (https://doi.org/10.1176/appi.psy.50.4.317)

51

BroekhofRGosselinkMJPijlHGiltayEJ. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. General Hospital Psychiatry 2012 34 209.e1209.e3.

52

Santos AndradeEHPanPMda SilvaPFGadelhaA. New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature. Case Reports in Medicine 2010 2010 573252.

53

LiuWZahrRSMcCartneySCetasJSDoganAFleseriuM. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary 2018 Epub.

Index Card

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 80 80 80
Full Text Views 106 106 106
PDF Downloads 48 48 48